- Home
- CBRE vs ALNY Comparison
CBRE vs ALNY Comparison
Compare CBRE & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBRE | ALNY |
|---|---|---|
| Founded | 1906 | 2002 |
| Country | United States | United States |
| Employees | 44000 | 115 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.5B | 39.0B |
| IPO Year | 2001 | 2004 |
Fundamental Metrics
Financial Performance| Metric | CBRE | ALNY |
|---|---|---|
| Price | $130.93 | $303.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 28 |
| Target Price | $177.86 | ★ $471.00 |
| AVG Volume (30 Days) | ★ 2.5M | 811.8K |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.61 | ★ 206.88 |
| EPS | 1.07 | ★ 2.33 |
| Revenue | ★ $40,550,000,000.00 | $1,037,418,000.00 |
| Revenue This Year | $14.31 | $52.67 |
| Revenue Next Year | $9.06 | $31.48 |
| P/E Ratio | ★ $122.26 | $130.55 |
| Revenue Growth | 13.37 | ★ 22.88 |
| 52 Week Low | $121.69 | $283.10 |
| 52 Week High | $174.27 | $495.55 |
Technical Indicators
Market Signals| Indicator | CBRE | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 44.73 | 51.97 |
| Support Level | $127.04 | $299.75 |
| Resistance Level | $138.73 | $331.27 |
| Average True Range (ATR) | 3.77 | 9.35 |
| MACD | 0.25 | 1.45 |
| Stochastic Oscillator | 79.47 | 69.78 |
Price Performance
Historical ComparisonAbout CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm managed over $155 billion (at year-end 2025) for clients across diverse public and private real estate strategies.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.